EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> DBV Technologies revealed it expects to compile the information needed to resubmit a filing for approval of its peanut allergy drug in the third quarter. Shares in DBV rose 13% following the news. Statement 

> Exscientia named Andrew Douglas as its director of data engineering. Release 

> The British Library struck a property development deal that will create life sciences laboratory and office space in London. Statement (PDF)

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

> Summit Therapeutics dosed the first patient in a phase 3 trial of its treatment for Clostridium difficile infection. Top-line data are due in the second half of 2021. Release (PDF)

> ADC Therapeutics dosed the first patient in a phase 1 trial that is testing its anti-CD19 antibody-drug conjugate in combination with AstraZeneca’s Imfinzi. Statement 

> Markus Dangl joined Achilles Therapeutics as CSO. Dangl worked at Medigene and Roche earlier in his career. Release